使用抗血管内皮生长因子和抗神经纤毛蛋白-1纳米抗体对病理性血管生成进行联合治疗。
combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies.
作者信息
Mohseni Nastaran, Roshan Reyhaneh, Naderi Shamsi, Behdani Mahdi, Kazemi-Lomedasht Fatemeh
机构信息
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
出版信息
Iran J Basic Med Sci. 2020 Oct;23(10):1335-1339. doi: 10.22038/ijbms.2020.47782.11000.
OBJECTIVES
Emergence of resistant tumor cells to the current therapeutics is the main hindrance in cancer treatment. Combination therapy, which mixes two or more drugs, is a way to overcome resistant problems of cancer cells to current treatments. Nanobodies are promising tools in cancer therapy due to their high affinity as well as high penetration to tumor sites.
MATERIALS AND METHODS
Here, the inhibitory effect of mixtures of two nanobodies (anti-vascular endothelial growth factor (VEGF) and anti-neuropilin-1 (NRP-1) nanobodies) on tube formation of human endothelial cells and were analyzed.
RESULTS
Results showed that combination of two drugs significantly inhibited proliferation and tube formation of human endothelial cells. In addition, mixtures of two nanobodies inhibited angiogenesis in chick chorioallantoic membrane (CAM) assay efficiently compared with each individual nanobody.
CONCLUSION
Results highlight the efficacy of combination therapy of cancer compared with mono-therapy and promises development of novel anti-cancer therapeutics based on nanobodies targeting two or more targets of tumor cells.
目的
肿瘤细胞对当前治疗方法产生耐药性是癌症治疗的主要障碍。联合疗法将两种或更多药物混合使用，是克服癌细胞对当前治疗产生耐药问题的一种方法。纳米抗体因其高亲和力以及对肿瘤部位的高渗透性，是癌症治疗中有前景的工具。
材料与方法
在此，分析了两种纳米抗体（抗血管内皮生长因子（VEGF）和抗神经纤毛蛋白-1（NRP-1）纳米抗体）混合物对人内皮细胞管形成的抑制作用。
结果
结果表明，两种药物联合显著抑制了人内皮细胞的增殖和管形成。此外，与每种单独的纳米抗体相比，两种纳米抗体的混合物在鸡胚绒毛尿囊膜（CAM）试验中有效抑制了血管生成。
结论
结果突出了癌症联合疗法与单一疗法相比的疗效，并有望开发基于靶向肿瘤细胞两个或更多靶点的纳米抗体的新型抗癌疗法。
Zotero 插件